Hello Friends! Are you looking to invest in the stock market, or have you already invested? Would you like to know the predictions regarding the potential fluctuations in your shares? If so, you have landed on exactly the right page. On this page, you will find information regarding Sun Pharma share price history, Sun Pharma News, Sun Pharma owner, Sun Pharma share price tradingview, Sun Pharma share price target 2030, and much more. Furthermore, this page provides details on Sun Pharma‘s share price targets 2026, 2027, 2028, 2029, 2030, 2040, and beyond.
Sun Pharma Company Information
| Industry | Pharmaceuticals |
| Founded | 1983; 43 years ago |
| Founder | Dilip Shanghvi |
| Headquarters | Mumbai, Maharashtra, India |
| Key people | Dilip Shanghvi (MD) |
Sun Pharma Share Price Target Overview
- Current Price – 1,757.00
- Open – 1,756.00
- High – 1,764.70
- Low – 1,750.60
- Mkt cap – 4.22LCr
- P/E ratio – 38.65
- 52-wk high – 1,851.20
- 52-wk low – 1,548.00
- Dividend – 0.94%
- Qtrly div amt – 4.13
Sun Pharma Share Price Chart
Sun Pharma Share Price Target Tomorrow
| Sun Pharma Share Price Target Years | Sun Pharma Share Price Target |
| 2026 | ₹1860 |
| 2027 | ₹2000 |
| 2028 | ₹2150 |
| 2029 | ₹2300 |
| 2030 | ₹2500 |
Sun Pharma Share Price Target 2026
The target for Sun Pharma’s share price in 2026 is projected to range between ₹1850 and ₹1860. As of the end of April 2026, Sun Pharma’s share price stood at ₹1,757.00. Compared to the previous year, Sun Pharma’s share price has witnessed an increase this year.
Sun Pharma Share Price Target 2027
The target for Sun Pharma’s share price in 2027 is projected to range between ₹1990 and ₹2000. On 29 April 2026, Sun Pharma Share price NSE is 1,757.00 INR. Compared to last year, no significant difference has been observed in the share price of Sun Pharma. The share price has increased by approximately 100-150 rupees.
Sun Pharma Share Price Target 2030
The target for Sun Pharma’s share price in 2030 is projected to range between ₹2450 and ₹2500. Over the past several years, the company has generated substantial profits, and investors, too, have earned handsome returns proportionate to their shareholdings. We remain optimistic that the company will continue to generate profits in the future, thereby ensuring continued returns for its investors.
Risks and Challenges Of Sun Pharma Share Price
Here are 8 key factors affecting the growth of Sun Pharma share price:
1. High Valuation Concerns – Sun Pharma trades at premium valuation multiples (around 30+ P/E). If growth slows, the stock can correct sharply due to valuation pressure.
2. Slowdown in US Specialty Business – The company’s key growth driver—US specialty segment—is showing slower growth than expected, which can impact future earnings momentum.
3. Patent Expiry & Competition Risk – Flagship drugs like Ilumya may face biosimilar competition in coming years, which can reduce revenue and margins significantly.
4. Pricing Pressure in US Market – US healthcare policies and drug pricing controls can reduce margins, especially for high-priced specialty medicines.
5. High Cost of New Drug Launches – Launching specialty drugs requires heavy investment in R&D, marketing, and regulatory approvals, which increases costs and impacts profitability.
6. Debt Risk from Large Acquisition – The recent acquisition of Organon (multi-billion deal) increases financial leverage. Higher debt can pressure future earnings if integration is not smooth.
7. Global Regulatory Risks – Pharma companies face strict regulations (USFDA, etc.). Any compliance issue or warning can impact exports and stock price sharply.
8. Currency & Global Market Risk
- Export-driven business depends on USD/INR movement
- Geopolitical issues (Middle East, trade disruptions) can affect sales and margins
These external risks create volatility.
Read Also:- AU Small Finance Bank Share Price Target Tomorrow From 2026 to 2030 – Current Chart, Market Overview
Key Factors Affecting Growth Sun Pharma Share Price
Here are 8 key factors affecting the growth of Sun Pharma share price:
1. Growth in Specialty Drug Business – Sun Pharma’s specialty drugs (like dermatology and immunology products) are high-margin. Strong growth in this segment can significantly boost profits and share price.
2. Performance in US Market – The US is the biggest revenue contributor. Better sales, approvals, and market share in the US directly impact overall earnings growth.
3. New Drug Launches & Pipeline – A strong pipeline of new drugs and successful launches (especially specialty and complex generics) can drive long-term growth.
4. R&D Investment & Innovation – Higher spending on research helps develop high-value medicines. Successful innovation improves margins and long-term valuation.
5. Domestic India Business Growth – Steady growth in the Indian pharma market (chronic therapies, branded generics) provides stable revenue and supports share price.
6. Regulatory Approvals (USFDA & Others) – Faster approvals and clean compliance track record help avoid disruptions and support export growth.
7. Margin Expansion & Cost Control – Improvement in operating margins through cost control and better product mix increases profitability and investor confidence.
8. Global Expansion & Acquisitions – Strategic acquisitions and expansion into new markets (Europe, emerging markets) can increase revenue sources and diversify risk.
Sun Pharma Shareholding Pattern
| Promoter | 54.5% |
| FII | 15.9% |
| DII | 21.1% |
| Public | 8.5% |
Income Statement Of Sun Pharma
|
All values in INR
|
Mar 2025
|
Jun 2025
|
Sep 2025
|
Dec 2025
|
|---|---|---|---|---|
|
Revenue
|
129.59B
|
138.51B
|
144.78B
|
155.21B
|
|
Cost of goods sold
|
34.48B
|
28.15B
|
29.83B
|
29.45B
|
|
Cost of revenue
|
34.48B
|
28.15B
|
29.83B
|
29.45B
|
|
Research and development expenses
|
–
|
–
|
–
|
–
|
|
Total research and development expenses
|
–
|
–
|
–
|
–
|
|
Selling, general, and admin expenses
|
25.66B
|
28.02B
|
27.65B
|
28.92B
|
|
Operating expense
|
66.55B
|
76.65B
|
81.29B
|
85.13B
|
|
Total operating expenses
|
101.03B
|
104.79B
|
111.11B
|
114.58B
|
|
Operating income
|
28.56B
|
33.72B
|
33.67B
|
40.62B
|
|
Other non operating income
|
-12.90B
|
4.64B
|
4.70B
|
5.79B
|
|
EBT including unusual items
|
32.48B
|
31.63B
|
41.55B
|
42.07B
|
|
EBT excluding unusual items
|
30.98B
|
39.81B
|
41.55B
|
46.97B
|
|
Income tax expense
|
10.94B
|
8.70B
|
10.31B
|
8.26B
|
|
Effective tax rate
|
33.68%
|
27.51%
|
24.80%
|
19.63%
|
|
Other operating expenses
|
34.25B
|
41.62B
|
46.34B
|
48.89B
|
|
Net income
|
21.50B
|
22.79B
|
31.18B
|
33.69B
|
|
Net profit margin
|
16.59%
|
16.45%
|
21.54%
|
21.71%
|
|
Earnings per share
|
10.01
|
11.98
|
13.00
|
15.48
|
|
Interest and investment income
|
12.97B
|
–
|
–
|
–
|
|
Interest expense
|
-491.40M
|
-748.00M
|
-998.60M
|
-783.60M
|
|
Net interest expenses
|
12.48B
|
-748.00M
|
-998.60M
|
-783.60M
|
|
Depreciation and amortization charges
|
6.64B
|
7.01B
|
7.30B
|
7.32B
|
|
EBITDA
|
34.46B
|
39.63B
|
40.82B
|
46.53B
|
|
Gain or loss from assets sale
|
–
|
–
|
–
|
–
|
Hi, I’m Ronak, a news writer covering the latest updates in automobiles, education, smartphones, and trending topics. I focus on delivering simple, clear, and timely news to keep readers informed about what’s happening around the world.